Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trialnews2026-02-23T10:03:49+00:00February 23rd, 2026|Endpoints News|
MoonLake has ‘confidence’ ahead of FDA submission, discloses mid-stage arthritis winnews2026-02-22T16:00:51+00:00February 22nd, 2026|Endpoints News|
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and morenews2026-02-21T11:00:24+00:00February 21st, 2026|Endpoints News|
Vanda gets FDA approval for ‘franchise-extending’ antipsychoticnews2026-02-21T00:51:50+00:00February 21st, 2026|Endpoints News|
Grail’s cancer test faces new uncertainty after UK studynews2026-02-20T20:09:44+00:00February 20th, 2026|Endpoints News|
Ionis scraps Alzheimer’s drug for people with Down syndromenews2026-02-20T19:32:53+00:00February 20th, 2026|Endpoints News|
Supreme Court tariff ruling lets stand Trump’s authority to target pharma news2026-02-20T18:35:54+00:00February 20th, 2026|Endpoints News|
Candel prices offering, signs royalty deal; Calquence label expandsnews2026-02-20T14:57:17+00:00February 20th, 2026|Endpoints News|
Daiichi taps John Tsai to lead R&D as Ken Takeshita departsnews2026-02-20T14:38:30+00:00February 20th, 2026|Endpoints News|
Novartis to divest India unit to private equity-led consortium for $159M news2026-02-20T12:15:13+00:00February 20th, 2026|Endpoints News|
